Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Breast Cancer AND Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,852 result(s) found for: Breast Cancer AND Cancer. Displaying page 38 of 93.
    «« First « Previous 34  35  36  37  38  39  40  41  42  Next» Last»»
    EudraCT Number: 2006-005573-21 Sponsor Protocol Number: A4021004 Start Date*: 2007-01-26
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A TWO-ARM RANDOMIZED OPEN LABEL PHASE 2 STUDY OF CP-751,871 IN COMBINATION WITH EXEMESTANE VERSUS EXEMESTANE ALONE AS FIRST LINE TREATMENT FOR POSTMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR POSITIVE...
    Medical condition: Hormone receptor positive advanced breast cancer in postmenopausal women.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) NL (Temporarily Halted) GB (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003131-11 Sponsor Protocol Number: 1280-0022 Start Date*: 2018-12-11
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: XeneraTM-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemest...
    Medical condition: HR+ / HER2- metastatic breast cancer and non-visceral disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) GR (Completed) PT (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001862-41 Sponsor Protocol Number: CBYL719A2201 Start Date*: 2013-11-26
    Sponsor Name:Novartis Farmacéutica , S.A.
    Full Title: A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive...
    Medical condition: neoadjuvant hormone-receptor positive HER2-negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) IT (Completed) AT (Completed) BE (Completed) DE (Completed) NL (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-002662-40 Sponsor Protocol Number: AS.T.R.O.BC01-13 Start Date*: 2013-09-10
    Sponsor Name:AS.T.R.O.
    Full Title: PERtuzumab-trastuzumab plus lEetrozoLe In endocrine Sensitive breast cancer: a phase II neoAdjuvant study
    Medical condition: Stage II-IIIA operable breast cancer, HER2 positive and hormone receptor-positive, previously untreated
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2023-000156-38 Sponsor Protocol Number: 20230123SE Start Date*: 2023-05-04
    Sponsor Name:Semmelweis University, Department of Internal Medicine and Oncology
    Full Title: Value-based health economic comparative study of subcutaneous and intravenous trastuzumab-pertuzumab for HER-2 positive metastatic breast cancer based on patient reported outcomes.
    Medical condition: HER-2 positive advanced breast cancer, locally unresectable or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005063-16 Sponsor Protocol Number: IEO370 Start Date*: 2017-07-17
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: A randomized presurgical study with different schedules of exemestane in postmenopausal women with stage 0-II ER-positive breast cancer
    Medical condition: Postmenopausal ER positive breast cancer, waiting for surgery.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000287-29 Sponsor Protocol Number: ET-FES00119 Start Date*: 2014-08-13
    Sponsor Name:Università del Piemonte Orientale
    Full Title: EARLY PREDICTION OF EFFICACY OF ENDOCRINE THERAPY IN BREAST CANCER: PILOT STUDY AND VALIDATION WITH 18F FLUOROESTRADIOL (FES) PET/CT
    Medical condition: Patients with histologically or cytologically confirmed ER-positive MBC at first evidence of metastatic disease.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) DE (Ongoing) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000073-23 Sponsor Protocol Number: CRAD001YIC04 Start Date*: 2012-05-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center, expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrin...
    Medical condition: Estrogen receptor positive locally advanced or metastatic breast cancer in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) NL (Completed) SE (Completed) NO (Completed) ES (Completed) DK (Completed) FI (Completed) BE (Completed) CZ (Prematurely Ended) IT (Completed) HU (Completed) IE (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-001064-27 Sponsor Protocol Number: s55283 Start Date*: 2013-06-25
    Sponsor Name:University Hospitals Leuven
    Full Title: Placebo-controlled trial with vitamin D to prevent worsening/relieve aromatase inhibitor-induced musculoskeletal symptoms in breast cancer patients
    Medical condition: aromatase inhibitor-induced musculoskeletal symptoms in postmenopausal breast cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004429-25 Sponsor Protocol Number: TS-001-DK Start Date*: 2006-10-31
    Sponsor Name:Viborg Sygehus
    Full Title: A single cohort, open trial to evaluate the efficacy and safety of TachoSil in prevention of seroma formation following axillary lymph node dissection in women following surgery for breast cancer. ...
    Medical condition: Seroma formation in the axilla following axillary dissection of lymphnodes following surgery for breast cancer in women
    Disease: Version SOC Term Classification Code Term Level
    7.1 10040102 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004424-38 Sponsor Protocol Number: 011604QM Start Date*: 2017-11-16
    Sponsor Name:Queen Mary University of London
    Full Title: A phase II study investigating preoperative combination strategies for immunotherapy in patients with untreated, operable ER+, HER2-negative primary breast cancer.
    Medical condition: Untreated, operable ER+, HER2-negative primary breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005395-34 Sponsor Protocol Number: CTC-cDDP Start Date*: 2013-04-25
    Sponsor Name:Erasmus MC
    Full Title: Prospective evaluation of the predictive value of a circulating tumor cell (CTC) sensitivity profile to Cisplatin chemotherapy in metastatic breast cancer patients
    Medical condition: Metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002459-27 Sponsor Protocol Number: CL1-81694-003 Start Date*: 2017-12-14
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Phase I/II trial of S 81694 administered intravenously in combination with paclitaxel to evaluate the safety, pharmacokinetic and efficacy in metastatic breast cancer
    Medical condition: Metastatic Breast Cancer (mBC) and metastatic Triple Negative Breast Cancer (mTNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020826 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-000166-13 Sponsor Protocol Number: 24-02 Start Date*: 2005-05-12
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer.
    Medical condition: Histologically proven, resected breast cancer with ER and/or PgR positive tumors
    Disease: Version SOC Term Classification Code Term Level
    7.0 10057654 LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Prematurely Ended) SE (Completed) DE (Completed) ES (Completed) IE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-000604-25 Sponsor Protocol Number: R96-A6604-14-S22 Start Date*: 2015-05-02
    Sponsor Name:Danish Cancer Society Research Center
    Full Title: HBOT LYCA: Hyperbaric Oxygen Therapy to reduce Lymphoedema after Breast Cancer - an explorative clinical trial
    Medical condition: breast cancer related lymphedema
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-000808-10 Sponsor Protocol Number: PREDIX-HER2 Start Date*: 2014-11-12
    Sponsor Name:Karolinska University Hospital
    Full Title: PREDIX HER2 - Neoadjuvant response-guided treatment of HER2 positive breast cancer. Part of a platform of translational phase II trials based on molecular subtypes
    Medical condition: Primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006191 Breast cancer male NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-005205-30 Sponsor Protocol Number: PM0259CA222B0 Start Date*: 2006-09-06
    Sponsor Name:Pierre Fabre Medicament
    Full Title: Randomised phase II study of the combination of oral vinorelbine with capecitabine versus a sequential regimen of oral vinorelbine and capecitabine versus the combination of docetaxel and capecitab...
    Medical condition: Patients with metastatic breast cancer previously treated with anthracyclines
    Disease: Version SOC Term Classification Code Term Level
    7.1 10027475 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001829-76 Sponsor Protocol Number: ProsMaMa13.1 Start Date*: 2013-10-04
    Sponsor Name:Paula Diéguez García
    Full Title: INTERCOSTAL BRANCHES BLOCK IN THE MIDAXILLARY LINE VERSUS PARAVERTEBRAL BLOCK, ULTRASOUND-GUIDED FOR NOT RECONSTRUCTIVE BREAST SURGERY. RANDOMIZED CLINICAL TRIAL
    Medical condition: Sheduled patients for nor reconstructive unilateral breast surgery
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003581-41 Sponsor Protocol Number: J2J-MC-JZLA Start Date*: 2020-09-08
    Sponsor Name:Eli Lilly and Company
    Full Title: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select ...
    Medical condition: ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-004028-11 Sponsor Protocol Number: BIOV-211 Start Date*: 2005-03-22
    Sponsor Name:Bioenvision Limited
    Full Title: A Phase II, Non-randomised, Study of Modrenal (Trilostane) in Pre-menopausal Women with Oestrogen Receptor Positive Breast Cancer who have Relapsed or are Refractory to Hormone Therapies of Tamoxif...
    Medical condition: Oestrogen Receptor Positive Breast Cancer who have Relapsed or are Refractory to Hormone Therapies of Tamoxifen, Goserelin and an Aromatase Inhibitor
    Disease: Version SOC Term Classification Code Term Level
    7.0 10057654 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 34  35  36  37  38  39  40  41  42  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 02 23:33:17 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA